Synthetic Biology and Materials Science: Redefining Entire Industries

It’s not often that materials science headlines grab attention, but when synthetic biology joins the mix, the results are staggering. Think bio-fabricated leathers, biodegradable plastics, and other creations that promise to upend polluting industries. This is a glimpse into a greener, better future.

Michael Koeris Tapped to Lead Biology Investments for this $4B Government Agency

A $4 billion injection into synthetic biology investments? That’s serious money with serious implications. Michael Koeris, who’s heading this effort, is well-positioned to help guide which synbio innovations will shape the next decade.

Johnson & Johnson to Acquire Synthetic Biology Company Ambrx for $2 Billion

If a $2 billion acquisition doesn’t scream “we’re serious about synthetic biology,” what does? Johnson & Johnson snapped up Ambrx to supercharge their drug development capabilities, showcasing just how high the stakes have become.

Digital Twins to Advance Biomanufacturing

“Digital twins” sounds like sci-fi, but the reality is here: virtual replicas of biomanufacturing processes are making production faster, cheaper, and far more efficient. Think fewer mistakes, better outcomes, and optimized workflows.

DNA Synthesis—Is the Future Chemical, Enzymatic, or Both?

Here’s a good nerdy debate: the future of DNA synthesis. Should we stick with tried-and-true chemical methods, jump on the enzymatic bandwagon, or embrace a hybrid? This article explores the tech shaping synbio’s DNA toolkit.

Non-Model Organisms Expand the Repertoire of Synthetic Biology

Who says only model organisms get to have all the fun? By engineering non-traditional species, synthetic biologists are unlocking new capabilities in manufacturing, environmental science, and beyond. It’s a bold move—and one that’s paying off.